Aggressive mechanical clot disruption and low-dose intra-arterial third-generation thrombolytic agent for ischemic stroke: A prospective study

被引:131
作者
Qureshi, AI
Siddiqui, AM
Suri, MFK
Kim, SH
Ali, Z
Yahia, AM
Lopes, DK
Boulos, AS
Ringer, AJ
Saad, M
Guterman, LR
Hopkins, LN
机构
[1] SUNY Buffalo, Sch Med & Biomed Sci, Dept Neurosurg, Buffalo, NY 14209 USA
[2] SUNY Buffalo, Sch Med & Biomed Sci, Toshiba Stroke Res Ctr, Buffalo, NY 14209 USA
[3] Rush Presbyterian St Lukes Med Ctr, Dept Neurosurg, Chicago, IL USA
关键词
angioplasty; balloon catheters; ischemic stroke; snare; thrombolytics;
D O I
10.1097/00006123-200211000-00040
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
OBJECTIVE: We prospectively evaluated the. safety and effectiveness of aggressive mechanical disruption of clot in conjunction with intra-arterial administration of a low-dose third-generation thrombolytic agent (reteplase) to treat ischemic stroke in patients who were considered. poor candidates for intravenous alteplase therapy or who failed to improve after intravenous thrombolysis. Mechanical clot disruption was used if low-dose pharmacological to increase the recanalization rate thrombolysis was ineffective. This strategy was adopted to increase the recanalization without increasing the risk of intracerebral hemorrhage. METHODS: Patients were considered poor candidates for intravenous therapy because of severity of neurological deficits, interval from symptom onset to presentation of at least 3 hours, or recent major surgery. We administered a maximum total dose of 4 U of rete lace intra-arterially in 1-U increments via superselective catheterization. After the initial doses were administered, we performed mechanical angioplasty (for proximal occlusion) or snare manipulation (for distal occlusion) at the occlusion site if recanalization had not occurred. The remaining doses of thrombolytics were subsequently administered if required for further recanalization. Angiographic responses were graded using modified Thrombolysis in My dial Infarction (TIMI) criteria. Clinical evaluations were performed before and 24 hours, 7 to 10 and 1 to 3 months after treatment. RESULTS: Nineteen consecutive patients were treated (mean age, 64.3 +/-16.2 yr; 10 men). Initial National Institutes of Health Stroke Scale scores ranged from 11 to 42. Time from. onset to treatment ranged from 1 to 9 hours. Occlusion sites were in the following arteries: cervical internal carotid (n = 7), intracranial internal carotid (n = 1), middle cerebral (n = 9), and basilar (n = 2). Of the 19 patients; thrombolysis alone was used in 5 patients, angioplasty was performed in 11 patients, and snare maneuvers were used in 5 patients. Complete restoration of blood flow (modified TIMI Grade 4) was observed in 12 patients, near-complete restoration of flow (modified TIMI Grade 3) in 4 patients, minimal response (modified TIMI Grade 1) in 1 patient, and no response in 2 patients (modified TIMI Grade 0). Neurological improvement at 24 hours (decline Of at least 4 points in National Institutes of Health Stroke Scale score) was observed in seven patients. Five other patients experienced further improvement in National Institutes of Health Stroke Scale score at 7 to 10 days. No vessel rupture, dissection, or symptomatic intracranial hemorrhages were observed. At the time of follow-up evaluation, 7 of 19 patients were functionally independent. CONCLUSION: A high rate of recanalization and clinical improvement can be observed in patients with. ischemic stroke using low-dose thrombolytic agents with adjunctive mechanical disruption of clot. Moreover, this strategy may reduce the risk of intracerebral hemorrhage observed with thrombolytics.
引用
收藏
页码:1319 / 1327
页数:9
相关论文
共 28 条
[1]   Intravenous tissue-type plasminogen activator for treatment of acute stroke - The standard treatment with alteplase to reverse stroke (STARS) study [J].
Albers, GW ;
Bates, VE ;
Clark, WM ;
Bell, R ;
Verro, P ;
Hamilton, SA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (09) :1145-1150
[2]  
BARNWELL SL, 1994, AM J NEURORADIOL, V15, P1817
[3]   Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (Recombinant plasminogen activator) and front-loaded, accelerated alteplase (Recombinant tissue plasminogen activator) in patients with acute myocardial infarction [J].
Bode, C ;
Smalling, RW ;
Berg, G ;
Burnett, C ;
Lorch, G ;
Kalbfleisch, JM ;
Chernoff, R ;
Christie, LG ;
Feldman, RL ;
Seals, AA ;
Weaver, WD .
CIRCULATION, 1996, 94 (05) :891-898
[4]   Transcatheter snare removal of acute middle cerebral artery thromboembolism: Technical case report [J].
Chopko, BW ;
Kerber, C ;
Wong, W ;
Georgy, B .
NEUROSURGERY, 2000, 46 (06) :1529-1531
[5]   Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset - The ATLANTIS study: A randomized controlled trial [J].
Clark, WM ;
Wissman, S ;
Albers, GW ;
Jhamandas, JH ;
Madden, KP ;
Hamilton, S .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (21) :2019-2026
[6]   PROACT: A phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke [J].
del Zoppo, GJ ;
Higashida, RT ;
Furlan, AJ ;
Pessin, MS ;
Rowley, HA ;
Gent, M .
STROKE, 1998, 29 (01) :4-11
[7]   Intra-arterial prourokinase for acute ischemic stroke - The PROACT II study: A randomized controlled trial [J].
Furlan, A ;
Higashida, R ;
Wechsler, L ;
Gent, M ;
Rowley, H ;
Kase, C ;
Pessin, M ;
Ahuja, A ;
Callahan, F ;
Clark, WM ;
Silver, F ;
Rivera, F .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (21) :2003-2011
[8]   Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) [J].
Hacke, W ;
Kaste, M ;
Fieschi, C ;
von Kummer, R ;
Davalos, A ;
Meier, D ;
Larrue, V ;
Bluhmki, E ;
Davis, S ;
Donnan, G ;
Schneider, D ;
Diez-Tejedor, E ;
Trouillas, P .
LANCET, 1998, 352 (9136) :1245-1251
[9]   Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke - Emergency management of stroke (EMS) bridging trial [J].
Lewandowski, CA ;
Frankel, M ;
Tomsick, TA ;
Broderick, J ;
Frey, J ;
Clark, W ;
Starkman, S ;
Grotta, J ;
Spilker, J ;
Khoury, J ;
Brott, T .
STROKE, 1999, 30 (12) :2598-2605
[10]   TISSUE-PLASMINOGEN ACTIVATOR FOR ACUTE ISCHEMIC STROKE [J].
MARLER, JR ;
BROTT, T ;
BRODERICK, J ;
KOTHARI, R ;
ODONOGHUE, M ;
BARSAN, W ;
TOMSICK, T ;
SPILKER, J ;
MILLER, R ;
SAUERBECK, L ;
JARRELL, J ;
KELLY, J ;
PERKINS, T ;
MCDONALD, T ;
RORICK, M ;
HICKEY, C ;
ARMITAGE, J ;
PERRY, C ;
THALINGER, K ;
RHUDE, R ;
SCHILL, J ;
BECKER, PS ;
HEATH, RS ;
ADAMS, D ;
REED, R ;
KLEI, M ;
HUGHES, S ;
ANTHONY, J ;
BAUDENDISTEL, D ;
ZADICOFF, C ;
RYMER, M ;
BETTINGER, I ;
LAUBINGER, P ;
SCHMERLER, M ;
MEIROSE, G ;
LYDEN, P ;
RAPP, K ;
BABCOCK, T ;
DAUM, P ;
PERSONA, D ;
BRODY, M ;
JACKSON, C ;
LEWIS, S ;
LISS, J ;
MAHDAVI, Z ;
ROTHROCK, J ;
TOM, T ;
ZWEIFLER, R ;
DUNFORD, J ;
ZIVIN, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (24) :1581-1587